TTrialPathMatch Me to Trials
← Back to trials
RecruitingLVADFrailtyGI Bleed

Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future

Eligible age

18–100 yrs

Accepts

All genders

Locations

7 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Durable left ventricular assist devices (dLVAD) have been increasingly utilized since the mid to late 1990s, with an uptick of utility starting in 2010 following expanded indications for therapy to not only include a bridge to transplantation strategy, but also for those individuals who suffer from advanced heart failure (HF) and do not qualify for cardiac transplantation. Despite the decreasing size of the newest generation devices leading to a lessened occurrence of adverse events, bleeding and infection still remain a concern for clinicians, as well as a general lack of predictability towards adverse events in individuals with a dLVAD in place. There is a lack of description in the literature currently, regarding the interface between what the pump data provides and what is seen in clinical practice. There also is little known about the effects of what is provided in the pump data, in correlation to quality-of-life following dLVAD implantation. Therefore, the purpose of this study is to prospectively analyze normal and abnormal pump data through pump operations such as suction events, low flow alarms as well as other adventitious alarms, PI events and power cable disconnects greater than 20 seconds, from the HeartMate 3 ® dLVAD in order to clinically correlate this data to quality of life, frailty and other various medical conditions and adverse events as defined by the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs). This will be achieved through two aims: 1) Evaluate the effectiveness of dLVAD pump operations data on clinical practice application (quality of life, frailty and various medical conditions, and adverse events such as GIB, RHF, infection, hypertension, arrhythmias and stroke); and 2) Evaluate correlations and relationships of longitudinal normal and abnormal dLVAD pump operations data, to demographic and clinical variables. This study is the first study to evaluate HeartMate 3 ® dLVAD pump operations data over time for effectiveness in the clinical practice.

Sponsor: International Consortium of Circulatory Assist Clinicians

You may qualify if…

  • 18 years of age or older
  • Scheduled Heartmate 3 ® dLVAD implantation

You may not qualify if…

  • \<18 years of age
  • Scheduled for dLVAD that is NOT a Heartmate 3 (R) device

Where it's recruiting

California

San Francisco

Florida

Gainesville

Illinois

Chicago

Kansas

Kansas City

Minnesota

Rochester

South Carolina

Charleston

Utah

Salt Lake City

Source: ClinicalTrials.gov · NCT06039176 · last updated 2025-12-16

Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About · TrialPath